Leflunomide-associated tuberculosis? [1]

Rheumatology

Volumn 45, Issue 2, 2006, Pages 228-229

  Hocevar A ^c   Rozman, B ^c   Praprotnik, S ^c   Lestan, B ^c   Erzen D ^a   Petric, V ^b   Tomšič, Matija ^c  

^a UNIVERSITY CLINIC OF RESPIRATORY AND ALLERGIC DISEASES   (Slovenia)

^b General Hospital   (Slovenia)

^c UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GAMMA INTERFERON; GOLD DERIVATIVE; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 15; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; PYRIMIDINE NUCLEOTIDE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; B LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DISEASE PREDISPOSITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG MONITORING; ENZYME INHIBITION; FEMALE; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LETTER; LIPID PEROXIDATION; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; TUBERCULOSIS;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; TUBERCULOSIS, PULMONARY;

EID: 31544465286     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kei173     Document Type: Letter

References (13)

1. Praprotnik S, Rozman B, Tomsic M. New issues in tuberculosis. Ann Rheum Dis 2005;64:795.
2. Carmona L, Hernandez-Garcia C, Vadillo C et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003;30:1436-9.
3. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004;50:372-9.
4. Mladenovic V, Domljan Z, Rozman B et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995;38:1595-603.
5. Smolen JS, Kalden JR, Scott DL et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999;353:259-66.
6. Kalden JR, Schattenkirchner M, Sorensen H et al. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: A five-year followup study. Arthritis Rheum 2003;48:1513-20.
7. Cannon GW, Kremer JM. Leflunomide. Rheum Dis Clin North Am 2004;30:295-309.
8. Alldred A, Emery P. Leflunomide: A novel DMARD for the treatment of rheumatoid arthritis. Expert Opin Pharmacother. 2001;2:125-37.
9. Miceli-Richard C, Dougados M. Leflunomide for the treatment of rheumatoid arthritis. Expert Opin Pharmacother 2003; 4:987-97.
10. Manna SK, Mukhopadhyay A, Aggarwal BB. Leflunomide suppresses TNF-induced cellular responses: Effects on NF-κB, activator protein-1, c-Jun N-terminal protein kinase and apoptosis. J Immunol 2000;165:5962-9.
11. Bieber J, Kavanaugh A. Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments. Rheum Dis Clin North Am 2004; 30:257-70.
12. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261-5.
13. Keane J. Tumor necrosis factor blockers and reactivation of latent tuberculosis. Clin Infect Dis 2004:39:300-2.